On the Forefront of Healthcare Change
to Turn Innovative Science
into Value for Patients

Astellas’ raison d’être is to, “contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.” Based on this statement, we aim to stand on the forefront of healthcare change, turning innovative science into value for patients.

In an environment where many diseases with high unmet medical needs remain, there are higher expectations for the development of innovative medicines and better therapeutic solutions that can raise the quality of medical care for patients. 

As such, we continue to enhance our core capabilities to deliver innovative medical solutions in urology, oncology, immunology, nephrology and neuroscience as therapeutic areas with high unmet medical needs. Additionally, we are advancing new therapeutic areas including muscle disease and ophthalmology and new technologies and modalities, such as next-generation vaccines and regenerative medicine. We are creating innovation and accelerating our approach to scientific discovery by combining internal capabilities and strengths with external strengths.

We contribute to the long-term sustainability and value of society and fulfil our corporate social responsibility by improving Access to Health as a global health issue in order to respond to requests and expectations from the society. 

Guided by our shared values of Astellas Way, we are committed to these initiatives and to bringing together individuals from diverse backgrounds within Astellas to surmount national, regional and organizational barriers, and unite our people. 

We continue communication with our stakeholders, including patients and their families, healthcare personnel, shareholders, employees and the global community. Through persistent dialogue to create new value and by anticipating changes that are turned into opportunities which lead to continual business evolution, we will remain a company of choice. Thank you for your continued support.

May 2017
Yoshihiko Hatanaka
President and CEO